RxDoctor Payments Data

Matthew Dillon

Medical · Jonesville, MINPI 1508099649

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 573 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,437in general payments, 2019–2025

Across 573 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$878
  • AbbVie$758
  • Otsuka America Pharmaceutical, Inc.$660
  • Pfizer$651
  • AstraZeneca$623
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,23998%
  • Education$1982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,437 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol42$38,131
MounjaroTirzepatide35$36,937
VraylarCariprazine Hcl15$35,602
JardianceEmpagliflozin21$30,246
XareltoRivaroxaban35$28,042
EliquisApixaban30$27,804
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,314
OzempicSemaglutide13$12,385
Albuterol Sulfate HfaAlbuterol Sulfate125$4,348
Breo ElliptaFluticasone/Vilanterol11$4,261
Icosapent Ethyl12$2,656
Atorvastatin Calcium147$1,784
Levothyroxine Sodium151$1,730
CefuroximeCefuroxime Axetil75$1,404
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen62$1,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$623$38,13142 claims
Lilly USA, LLCMounjaro$878$36,93735 claims
AbbVieVraylar$758$35,60215 claims
GSKTrelegy Ellipta, Breo Ellipta$478$30,57540 claims
Boehringer IngelheimJardiance$121$30,24621 claims
Johnson & JohnsonXarelto$343$28,04235 claims
PfizerEliquis$651$27,80430 claims
Novo NordiskOzempic$1,411$12,38513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.

Other medical in Jonesville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →